Featured Articles

January 25, 2022
FeaturedPress Release

CSO, CFO, and GC added as technology-enabled pharma company bolsters growing management team and SAB SAN FRANCISCO, Calif. — January 25, 2022 — Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, announced today the appointment of David Thomson, Ph.D. as Chief Scientific Officer. Additional management team appointments include Jonathan Barr […]

Read Article
March 9, 2021
FeaturedPress Release

Recognized for innovation in powering small molecule drug discovery with AI, Atomwise among the Top-10 in Biotechnology category SAN FRANCISCO, Calif. — March 9, 2021 —  Atomwise, a leader in using artificial intelligence (AI) for small -molecule drug discovery, today announced it has been named to Fast Company’s prestigious annual list of the World’s Most […]

Read Article
December 21, 2020
FeaturedPress Release

Atomwise unveils a growing portfolio of emerging joint venture companies, with programs spanning oncology, immunology, infectious disease, neuroscience and clotting disorders. Atomwise CEO and joint venture companies are scheduled to speak at Informa’s Biotech Showcase from January 11-15, 2021 during J.P. Morgan Healthcare Week. SAN FRANCISCO, Calif., December 21, 2020 – Atomwise, the leader in […]

Read Article
December 18, 2020
FeaturedPress Release

A2i Therapeutics secures seed funding from FutuRx and its investors – Johnson & Johnson Innovation (JJDC, Inc.), Takeda Ventures, OrbiMed Partners, Leaps by Bayer and the Israeli Innovation Authority – to develop novel small molecule immuno-oncology agents. SAN FRANCISCO, CA and NESS ZIONA, Israel – December  18, 2020 – Atomwise, the leader in using artificial […]

Read Article